Patient clustering by serum inflammatory mediators stratifies early disease-modifying antirheumatic drug-naïve rheumatoid arthritis and reveals distinct pathobiological signatures: a prospective observational cohort
Authors' conclusion
Baseline serum inflammatory mediator profiles can stratify DMARD-naive patients with early RA into subgroups with distinct pathobiological mechanisms.
Study context
- Population
- Disease-modifying anti-rheumatic drug (DMARD)-naive patients with early rheumatoid arthritis (RA) from a prospective cohort
- Participants
- 204 patients
- Comparison
- Cluster 1 vs cluster 2 defined by baseline serum inflammatory mediator profiles
Methodological detailsexploratory, hypothesis-generating, unsupervised hierarchical clustering
- Exploratory
- Hypothesis-generating
- Unsupervised hierarchical clustering
Primary result
As reported in the abstract
Patient clusters by 13 baseline serum inflammatory mediators
Low RF titre identified the IL-6-driven subgroup (AUC), in contrast to CRP
0.785
Original publication
Patient clustering by serum inflammatory mediators stratifies early disease-modifying antirheumatic drug-naïve rheumatoid arthritis and reveals distinct pathobiological signatures: a prospective observational cohort. Clin Exp Rheumatol. Published 20 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →